Coreline Soft Accelerates Expansion of Its AI Medical Diagnosis Ecosystem with Consecutive National and Municipal Project Selections

• Building Next-Generation Medical AI Infrastructure…
• Expanding Early Diagnosis from National Projects to Global Markets…
• Advancing Beyond Lung Disease into Multimodal Healthcare
   

Coreline Soft (CEO: Jinkook Kim), a leading medical artificial intelligence (AI) company, has been consecutively selected for major R&D projects, reinforcing both its technological capabilities and business potential.

Most recently, the company was chosen for the 2025 Seoul Testbed Demonstration Program, supported by the Seoul Metropolitan Government and the Seoul Business Agency. Under this initiative, Coreline Soft will conduct a pivotal clinical trial for regulatory approval of its AI software for pulmonary embolism (PE) diagnosis, AVIEW iPE, at the Catholic University of Korea Eunpyeong St. Mary’s Hospital (Principal Investigator: Prof. Jin-Young Yoo, Department of Radiology). The program is designed to validate innovative technologies in real-world settings and bridge them toward commercialization.

Through this demonstration, Coreline Soft aims to launch a software solution that detects pulmonary embolism—often overlooked in routine chest CT—thereby solidifying its leadership position in the chest CT market.
In parallel, the company has also joined a national multimodal AI project, combining CT-based multi-disease analysis with generative AI to initiate development of a next-generation medical AI platform.

CEO Jinkook Kim commented:
“Being consecutively selected for Seoul City’s programs and launching our multimodal AI research underscores both Coreline’s technological differentiation and its potential for global commercialization. Beyond the early detection of major causes of mortality such as pulmonary and cardiovascular diseases, our long-term vision is to establish a global standard platform for personalized health screening powered by multimodal AI.”

The medical AI industry is no longer experimental—it is rapidly becoming the core infrastructure of national screening programs, public health systems, and global healthcare delivery. In high-burden areas such as lung cancer, cardiovascular disease, and pulmonary embolism, AI is emerging as a practical solution that enhances diagnostic accuracy and efficiency while reducing physician workload and addressing regional disparities in care.

Meanwhile, Coreline Soft will officially unveil AVIEW 2.0 at the Korean Congress of Radiology (KCR 2025), to be held at COEX in Seoul from September 24–27. AVIEW 2.0 has been significantly enhanced with user experience (UX) features aligned to real-world radiology workflows and expanded technical integration, marking a major step forward in transforming the clinical reading environment.